Compounds in clinical Phase III and beyond.

Kessler, Torsten; Bayer, Michael; Schwöppe, Christian; Liersch, Rüdiger; Mesters, Rolf M; Berdel, Wolfgang E

Kessler, Torsten; Bayer, Michael; Schwöppe, Christian; Liersch, Rüdiger; Mesters, Rolf M; Berdel, Wolfgang E.

Affiliation

Kessler T; Department of Medicine, Hematology and Oncology, University of Münster, Albert-Schweitzer-Strasse, 33, 48129, Münster, Germany. torstenkessler@uni-muenster.de

Recent Results Cancer Res ; 180: 137-63, 2010.

Article in En | MEDLINE | ID: mdl-20033382

Subject(s)

Angiogenesis Inhibitors/therapeutic use; Neoplasms/drug therapy; Axitinib; Benzenesulfonates/therapeutic use; Clinical Trials, Phase III as Topic; Endostatins/therapeutic use; Humans; Imidazoles/therapeutic use; Indazoles/therapeutic use; Indoles/therapeutic use; Niacinamide/analogs & derivatives; Phenylurea Compounds; Pyridines/therapeutic use; Pyrroles/therapeutic use; Sorafenib; Sunitinib; Thalidomide/therapeutic use; Vascular Endothelial Growth Factor A/antagonists & inhibitors

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Angiogenesis Inhibitors / Neoplasms Limits: Humans Language: En Journal: Recent Results Cancer Res Year: 2010 Document type: Article Affiliation country: Germany Country of publication: Germany

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google